Gilead Sciences Inc Stock (GILD) Closed Up by 3.04% on May 22: Drivers Behind the Movement
Gilead Sciences Inc. (GILD) stock closed up by 3.04% on May 22, outperforming its sector, driven primarily by significant advancements in its product pipeline and regulatory milestones. Key drivers include the FDA approval of Hepcludex for chronic hepatitis delta virus infection and the European Medicines Agency's positive recommendation for Trodelvy in advanced breast cancer. Despite some reports of insider selling and a lowered Q4 2026 EPS estimate, these positive developments provided a strong catalyst for the stock's upward movement.
Final trades: AbbVie, Millrose Properties, Archer-Daniels-Midland, GE Vernova and Estee Lauder
This article lists several companies, including AbbVie, Millrose Properties, Archer-Daniels-Midland, GE Vernova, and Estee Lauder, under the heading "Final trades". Without additional content, the specific context or recommendation for these trades cannot be determined.
Final Trades: AbbVie, Millrose Properties, Archer-Daniels-Midland, GE Vernova and Estee Lauder
The article highlights the "Halftime Report" Investment Committee's top stock picks for the remainder of the trading day. The featured companies are AbbVie, Millrose Properties, Archer-Daniels-Midland (ADM), GE Vernova, and Estee Lauder. The segment suggests these stocks are noteworthy for investors.
AbbVie, Merck, Astra among winners of EU drug recommendations this week
The EU drug regulator's expert panel has recommended eight new medicines for approval this week, benefiting companies like Merck, AstraZeneca, and AbbVie. Merck's Keytruda, AstraZeneca's Enhertu, and AbbVie's Maviret received positive opinions for new indications, suggesting expanded market access and potential revenue growth. Pending final decisions from the European Commission could significantly impact the future revenue streams for these drugmakers by unlocking new sales volumes for larger or new patient groups.
AbbVie (ABBV) Receives Positive EMA Opinion for Maviret Approval
AbbVie (ABBV) has received a positive opinion from the European Medicines Agency for its oral antiviral treatment, Maviret, targeting acute hepatitis C infections in adults and children. This could significantly enhance AbbVie's market presence in virology if the European Commission confirms approval in Q3 2026. However, a high P/E ratio and recent insider selling of $9.5 million worth of shares suggest potential caution for investors despite the positive development.
AbbVie Announces Positive CHMP Opinion for MAVIRET® for the Treatment of Acute Hepatitis C Infection
AbbVie announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the approval of MAVIRET® (glecaprevir/pibrentasvir) for the treatment of acute hepatitis C infection (HCV) in adults and children aged 3 years and older. This positive opinion is supported by data from the Phase 3 M20-350 study, which evaluated the safety and efficacy of MAVIRET, demonstrating a 96% cure rate. If approved by the European Commission, MAVIRET would be indicated for both acute and chronic HCV infection, aiding in earlier treatment, reducing transmission, and supporting global HCV elimination efforts.
Opinion: AbbVie Is the Best Dividend King to Buy in an Increasingly Uncertain Market
In uncertain market conditions, Dividend Kings—stocks that have increased dividends for at least 50 consecutive years—are often favored. The article argues that AbbVie (NYSE: ABBV) stands out among these for its stable business, attractive dividend yield of over 3.2%, reasonable valuation (14.7x forward earnings), and strong growth prospects, particularly after successfully navigating the Humira patent cliff with its successor drugs. While other Dividend Kings may have shortcomings in yield, valuation, or growth, AbbVie is presented as a balanced choice for income, value, and long-term growth investors.
Opinion: AbbVie Is the Best Dividend King to Buy in an Increasingly Uncertain Market
The article suggests AbbVie (NYSE: ABBV) as the top "Dividend King" pick for investors during uncertain market conditions. It highlights AbbVie's stable business, attractive dividend yield (over 3.2%), consistent dividend increases for 53 years, and a favorable valuation with a forward P/E ratio of 14.7. The company's successful navigation of the Humira patent cliff and strong growth prospects with successors like Rinvoq and Skyrizi are also emphasized.
AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline
AbbVie (NYSE: ABBV) announced new data at the 2026 ASCO Annual Meeting, showcasing the depth and breadth of its oncology pipeline, specifically in solid tumors and blood cancers. The presentations highlight the company's focus on innovative therapies, including antibody-drug conjugates (ADCs) and T-cell engagers (TCEs), demonstrating promising results in various difficult-to-treat cancers such as metastatic castration-resistant prostate cancer, small cell lung cancer, platinum-resistant ovarian cancer, and multiple myeloma. These findings underscore AbbVie's commitment to addressing critical unmet patient needs through diversified and differentiated therapeutic approaches.
Allergan Aesthetics Receives Positive CHMP Opinion for Boey® for the Temporary Improvement of Moderate to Severe Glabellar Lines in Adults
Allergan Aesthetics, an AbbVie company, announced that Boey® (trenibotulinumtoxinE) has received a positive opinion from the European Medicines Agency's CHMP for the temporary improvement of moderate to severe glabellar lines. This approval would cover 30 EU & EEA markets and positions Boey® as potentially the first and only botulinum neurotoxin serotype E for this indication, offering rapid results within 8 hours and lasting 2-3 weeks. The positive opinion is based on data from two pivotal Phase 3 trials showcasing its efficacy and safety.
AbbVie (ABBV) Receives Positive EMA Opinion for Boey Approval
AbbVie (ABBV) received a positive opinion from the European Medicines Agency (EMA) for Boey, a product designed to improve moderate to severe frown lines, paving the way for its market entry in 30 European Economic Area countries. While this enhances AbbVie's aesthetics portfolio, the company's stock shows a high P/E ratio of 105.91x compared to its historical median, and insiders have sold $9.5 million worth of shares, suggesting a cautious outlook despite a strong GF Score™ of 81.
[PREC14A] Seer, Inc. Preliminary Contested Proxy Statement
This preliminary contested proxy statement from the Radoff-JEC Group outlines their intent to nominate three highly qualified directors to Seer, Inc.'s Board at the 2026 Annual Meeting. The group, holding approximately 7.8% of outstanding Common Stock, argues that significant board changes are necessary due to Seer's poor financial performance, consistent stock undervaluation compared to its net cash, and questionable corporate governance practices. They advocate for a strategic review and a potential sale of the company to maximize stockholder value.
EU advisers back Allergan’s Boey, a wrinkle shot that works in 8 hours
Allergan Aesthetics, an AbbVie company, received a positive opinion from the CHMP for its product Boey (trenibotulinumtoxinE) for the temporary improvement of moderate to severe glabellar lines in adults. The recommendation covers 30 EU/EEA markets and is supported by two Phase 3 trials showing rapid onset of effect within 8 hours and efficacy lasting 2-3 weeks, with a safety profile similar to placebo. This moves the company closer to potential European Commission approval and commercial launch, expanding its aesthetics portfolio in Europe.
Genmab to Highlight Advances Across Its Oncology Portfolio
Genmab will present 23 abstracts at the 2026 ASCO Annual Meeting and EHA 2026 Congress, showcasing data from its epcoritamab development program including four oral presentations. The presentations will highlight epcoritamab’s versatility as monotherapy and in combination regimens for various B-cell malignancies. Additionally, data on investigational late-stage medicines, rinatabart sesutecan and petosemtamab, will be featured.
Lilly, AbbVie, J&J, AZ lead an uptick in Big Pharma Q1 growth, with Novo again bringing up the rear
The first quarter of this year saw an uptick in biopharma sales, with eight of the top-25 companies achieving double-digit year-over-year growth, compared to six in each quarter of 2025. Eli Lilly led the growth with a 56% increase, extending its reign as the top performer for six consecutive quarters. Other significant contributors to this growth included Regeneron, AstraZeneca, AbbVie, Sandoz, Johnson & Johnson, Astellas, and Daiichi Sankyo, while Novo Nordisk experienced the largest sales decline for the second consecutive quarter.
AbbVie Inc. stock underperforms Thursday when compared to competitors despite daily gains
Shares of AbbVie Inc. (ABBV) increased by 1.04% on Thursday, closing at $214.50, despite the broader market also experiencing gains. However, this performance meant the stock underperformed compared to its competitors. The company's stock is currently 12.38% below its 52-week high of $244.81, achieved on October 1st.
Opinion: This program was meant to increase healthcare affordability. The data tell another story.
An op-ed by Carter Dutch argues that the 340B drug discount program, intended to improve healthcare affordability, is failing in its objective and requires a complete overhaul. This commentary, published by Crain's Chicago Business, suggests that the program's current data indicate it is not achieving its stated goals.
Precision Trading with Abbvie Inc. (ABBV) Risk Zones
This article provides an in-depth analysis of Abbvie Inc. (ABBV) using AI-generated signals and quantitative research. It highlights a strong overweight bias across all time horizons and outlines specific trading strategies. The analysis also details support and resistance levels for near-term, mid-term, and long-term trading, guiding traders with identified risk zones and risk-reward ratios.
CytomX Therapeutics to Present at Upcoming June Investor Conferences
CytomX Therapeutics announced that its management will participate in two investor conferences in June: the Jefferies Global Healthcare Conference on June 4, 2026, and the Goldman Sachs 47th Annual Global Healthcare Conference on June 10, 2026. The company, which focuses on developing conditionally activated biologics for cancer treatment, will provide a live webcast of its presentations and be available for one-on-one meetings with investors at both events.
AbbVie Inc stock (US00287Y1091): new data, dividend strength and oncology focus draw investor attent
AbbVie is navigating a significant transition away from its reliance on Humira, focusing instead on its immunology, oncology, neuroscience, and aesthetics portfolios. The company's strategy involves continued development in these key areas, as evidenced by recent clinical data and earnings reports, while maintaining a strong dividend policy. For investors, AbbVie presents an opportunity to invest in diverse therapeutic markets with a recognized dividend profile, though it is subject to the inherent risks of drug development and regulatory environments.
AbbVie stock (US00287Y1091): focus on immunology pipeline after latest data update
AbbVie Inc. is garnering renewed investor attention due to fresh clinical data from its immunology portfolio and the continued emphasis on newer drugs like Skyrizi and Rinvoq, which are intended to offset declining revenue from Humira. The company is actively diversifying its revenue streams through acquisitions and an extensive R&D pipeline in key therapeutic areas like immunology, oncology, neuroscience, and aesthetics. Investors are closely monitoring how effectively AbbVie can navigate the transition from its reliance on Humira and maintain growth amidst increasing competition and evolving market dynamics.
Is Aldeyra Therapeutics on the Brink of a Breakthrough with Reproxalap
Aldeyra Therapeutics is approaching a critical FDA PDUFA date of March 16, 2026, for its dry eye drug, reproxalap, following two prior Complete Response Letters. The company has addressed previous FDA concerns with new clinical data, leading to a resubmission and an extended review period, which could suggest a more thorough regulatory path. If approved, reproxalap has the potential to activate a significant partnership with AbbVie, offering Aldeyra a substantial financial injection and leveraging AbbVie's market infrastructure.
High Yield Healthcare Stocks: Why Pfizer, AbbVie, and Medtronic Are Worth Watching in 2026
This article examines three high-yield healthcare stocks—Pfizer, AbbVie, and Medtronic—detailing their unique dividend profiles and business models for income investors looking at 2026. Pfizer offers the highest yield with business challenges, AbbVie presents a balanced growth story with new drug successes, and Medtronic stands out for its consistent dividend history as a medical technology company. Each company provides a different risk-reward proposition driven by factors such as patent expirations, new drug pipelines, and market stability.
Before Buying Regenxbio Inc (RGNX) Stock, Check Out the Cash Runway
Regenxbio Inc. reported its Q1 2026 financial results, exiting the quarter with $150.5 million in cash, which is expected to fund operations into early 2027. The company announced positive Phase 3 trial results for its RGX-202 gene therapy for Duchenne and anticipates a $100 million milestone payment from AbbVie related to their partnered retinal treatment program. While the article highlights RGNX's potential, it also suggests that some AI stocks may offer higher returns in a shorter timeframe.
AbbVie stock (US00287Y1091): investors eye Skyrizi and Rinvoq momentum after latest quarterly update
AbbVie's latest quarterly results show a continued transition away from its former blockbuster drug Humira, with significant growth from immunology drugs Skyrizi and Rinvoq, as well as contributions from aesthetics and neuroscience segments. While Humira sales decline, the company's diversified portfolio aims to reshape its earnings profile. Investors are watching its performance amidst regulatory developments and competitive pressures in the pharmaceutical industry.
Agilysys And Two Other Stocks Priced Below Estimated Value
This article identifies several undervalued U.S. stocks based on discounted cash flow analysis, focusing on Agilysys, Ouster, and Super Group (SGHC). Despite a recent market decline, these companies are highlighted for their significant discounts to fair value and strong projected earnings or revenue growth. The piece offers a brief overview of each company's operations and financial outlook, recommending them as potential investment opportunities.
Nektar Names Linda Rubinstein CFO As Funding And Dilution Questions Loom
Nektar Therapeutics has appointed Linda Rubinstein as its new Chief Financial Officer, succeeding Sandra Gardiner. This leadership change comes as Nektar, a loss-making biopharmaceutical company, faces significant funding and potential dilution questions, particularly after a recent $150 million equity offering. Rubinstein's extensive background in capital-raising and M&A in development-stage life sciences companies is expected to be crucial in managing the company's financial strategy, clinical programs, and partnerships, as investors closely monitor her approach to cash runway and future equity issuance.
Genmab A/S stock (DK0010272202): revenue growth and pipeline in focus after latest quarterly report
Genmab A/S has released its latest quarterly figures, highlighting continued revenue growth driven by royalties from key partnered products and milestone payments. The biotech firm, which specializes in antibody-based cancer therapies, remains focused on its oncology pipeline and strategic partnerships. The report detailed Q1 2026 financial results, R&D expenses, and reaffirmed its guidance, underscoring its hybrid business model of proprietary research and collaborations with larger pharmaceutical companies.
WisdomTree US SmallCap Dividend Fund Faces Payout Durability Questions
The WisdomTree U.S. SmallCap Dividend Fund (NYSEARCA:DES) distributes monthly dividends, but their consistency and long-term sustainability are under scrutiny due to significant monthly fluctuations and a fund design heavily weighted in cyclical sectors. While macroeconomic strength, evidenced by robust corporate profits, currently supports the underlying companies' ability to sustain payouts, investors relying on these distributions are advised to focus on annualized totals rather than inconsistent monthly figures. The fund's unique index weighting, based on the absolute dollar amount of dividends paid, restricts its ability to shift to safer defensive equities during market stress, posing a potential vulnerability.
EDSA Stock Price, Quote & Chart | EDESA BIOTECH INC (NASDAQ:EDSA)
This article provides a detailed overview of EDESA BIOTECH INC (NASDAQ: EDSA) stock, including its current price, performance statistics, and technical and fundamental analysis ratings from ChartMill. It also covers the company's earnings history, analyst forecasts, financial highlights, ownership structure, and industry overview within the Biotechnology sector. Additionally, the article includes recent news and a company profile detailing Edesa Biotech's focus on medical dermatology and respiratory diseases.
AbbVie Inc. stock outperforms competitors on strong trading day
AbbVie Inc. (ABBV) shares rose 2.08% to $213.76 on Tuesday, outperforming the broader market which saw the S&P 500 Index and Dow Jones Industrial Average decline. This gain broke a two-day losing streak for the stock.
Ditch or Double Down on This Pharma ETF as Trump Adjusts Drug Prices?
The iShares U.S. Pharmaceuticals ETF (IHE) has surprisingly outperformed healthcare benchmarks, returning 38% over twelve months despite former President Trump's "most favored nation" drug pricing executive order. This outperformance is largely driven by concentrated holdings in Eli Lilly and AbbVie, raising concerns about concentration risk. While the ETF has benefited from GLP-1 economics and depressed valuations, policy implementation risks regarding Medicare drug price negotiation still loom, suggesting caution for retirement investors.
AbbVie (ABBV) Price Target Lowered to $235 at Evercore ISI
Evercore ISI has slightly lowered its price target for AbbVie (ABBV) from $236 to $235, while maintaining an 'Outperform' rating. This adjustment follows AbbVie's mixed Q1 results, where earnings per share fell slightly below estimates, but revenue exceeded expectations with a 12% year-over-year growth, driven by new immunology drugs. The company also raised its full-year 2026 adjusted EPS and net revenue guidance.
Neurocrine Biosciences Presents Real-World Data Highlighting Functional Impact of Mild Tardive Dyskinesia Severity and Improvement with INGREZZA® (valbenazine) Capsules
Neurocrine Biosciences announced new real-world data showing that even mild tardive dyskinesia (TD) significantly impairs daily functioning, and treatment with INGREZZA® (valbenazine) capsules leads to substantial improvements. A clinician survey indicated that 90% of patients with mild TD experienced emotional, social, or physical impairment, with 96% showing improved uncontrolled movements after INGREZZA initiation, and functional status improvements across various daily activities. These findings, presented at the American Psychiatric Association 2026 Annual Meeting, reinforce INGREZZA's benefits for individuals with TD, including those with mild symptoms.
AbbVie Inc stock (US00287Y1091): new oncology data and pipeline updates keep focus on long-term grow
AbbVie Inc. is actively diversifying its portfolio beyond Humira, with a strong focus on oncology, neuroscience, and aesthetics. Recent clinical data and pipeline updates for immunology drugs like Skyrizi and Rinvoq, as well as advancements in hematologic cancers, aim to drive long-term growth. The company strategy balances significant R&D investments, targeted acquisitions, and dividend commitments to shareholders, while navigating challenges posed by biosimilar competition and healthcare policy changes.
Ill. Panel Sides With AbbVie In Eye-Stent Injury Suit
An Illinois appeals panel affirmed summary judgment in favor of AbbVie in a lawsuit where a plaintiff alleged an eye stent caused injuries. The panel found that the patient failed to provide evidence linking his symptoms to a manufacturing or design defect in the product. The decision exonerates AbbVie from liability in this specific eye-stent injury claim.
Here's How Neuroscience Drugs Boost AbbVie's Q1 Sales Growth
AbbVie's neuroscience franchise significantly boosted its Q1 2026 sales, largely driven by strong demand for drugs like Vraylar, Ubrelvy, Qulipta, Botox Therapeutic, and Vyalev. The company reported $2.88 billion in neuroscience revenues, a 26% year-over-year increase, helping to offset declining Humira sales. AbbVie is also looking to expand its neuroscience portfolio with new offerings like tavapadon for Parkinson's disease, while facing competition from other major players like Biogen and Johnson & Johnson.
Assessing Biogen (BIIB) Valuation After Recent Share Price Momentum And Earnings Expectations
Biogen (BIIB) stock has seen recent momentum with an 8.8% gain over the past month and a 49.1% one-year total return, yet it trades at $192.95, which is 55.2% below one intrinsic value estimate and a 13.6% discount to an analyst target. The company's most followed narrative suggests a fair value of $205.67, driven by expanding global access to key therapies and a diverse pipeline, though risks from new drug launches and competition exist. While the narrative indicates undervaluation, Biogen's P/E ratio of 20.8x is higher than its industry and peers, suggesting a balanced valuation.
Biogen completes acquisition of Apellis Pharmaceuticals
Biogen has completed its acquisition of Apellis Pharmaceuticals, integrating its geographic atrophy treatment SYFOVRE into Biogen's immunology and complement-focused portfolio. This acquisition, valued at approximately $5.6 billion, is expected to have limited near-term clinical implications for retina specialists but holds potential long-term significance for SYFOVRE's development and commercialization. The article also reviews SYFOVRE's clinical background, mechanism of action, pivotal trial evidence, and safety profile, including postmarketing reports of retinal vasculitis and increased risk of nAMD.
Lilly's Daniel Skovronsky joins Bernstein fireside chat on May 28
Eli Lilly and Company (LLY) announced that Daniel M. Skovronsky, chief scientific and product officer and president of Lilly Research Laboratories, will participate in a fireside chat at Bernstein's 42nd Annual Strategic Decisions Conference on May 28, 2026, at 1:30 p.m. Eastern time. A live audio webcast and a 90-day replay will be available on Lilly's investor website. This participation continues Lilly's active investor communication following recent positive clinical and strategic updates.
CytomX appoints Mamata Gokhale as regulatory affairs head
CytomX Therapeutics has appointed Mamata Gokhale, Ph.D., RAC, as its Senior Vice President of Regulatory Affairs. Dr. Gokhale will lead the company's global regulatory strategy, bringing over 25 years of experience in the field. The company, focused on cancer treatments, reported strong Q1 2026 earnings, exceeding analyst expectations, despite a recent stock decline.
Mission Wealth Management LP Lowers Holdings in AbbVie Inc. $ABBV
Mission Wealth Management LP significantly reduced its stake in AbbVie Inc. by 20.5% in the fourth quarter, selling 9,597 shares, though it still holds 37,264 shares valued at $8.5 million. Despite this, other major institutional investors like Vanguard and Wellington Group increased their holdings, and institutions collectively own 70.23% of AbbVie’s stock. AbbVie recently surpassed earnings and revenue expectations and has a consensus price target of $253.43 with a "Moderate Buy" rating from analysts.
TD Private Client Wealth LLC Sells 9,822 Shares of AbbVie Inc. $ABBV
TD Private Client Wealth LLC reduced its stake in AbbVie Inc. by 12.6% in the fourth quarter, selling 9,822 shares to hold 68,073 shares valued at approximately $15.6 million. This reduction comes as AbbVie reported strong quarterly earnings, beating analyst estimates with $2.65 EPS and $15 billion in revenue, driven by the success of Skyrizi and Rinvoq. Analysts maintain a "Moderate Buy" rating on the stock with an average price target of $253.43, and institutional ownership stands at 70.23%.
60,762 Shares in AbbVie Inc. $ABBV Acquired by North Dakota State Investment Board
The North Dakota State Investment Board recently acquired 60,762 shares of AbbVie Inc. (NYSE:ABBV) during the fourth quarter, valuing their new position at approximately $13.88 million. This acquisition makes AbbVie the 23rd largest holding for the board, constituting 0.5% of its total holdings. The article also details other institutional investor activity, insider trading, recent analyst ratings, financial performance, and dividend information for AbbVie.
Cannabis Pharmaceuticals Business Research Report 2026: An $111.1 Billion Market by 2032 from $4.7 Billion in 2025 Featuring AbbVie, Aphria, Aurora Cannabis, Bausch Health, and Canopy Growth
The global cannabis pharmaceuticals market is projected to reach $111.1 billion by 2032, growing from $4.7 billion in 2025 at a CAGR of 57.1%. This significant growth is primarily driven by increasing medical cannabis legalization, substantial R&D investments, and a rising demand for alternative treatments for chronic pain, neurological disorders, and mental health conditions. Key players in this evolving market include AbbVie, Aphria, Aurora Cannabis, Bausch Health, and Canopy Growth.
AbbVie stock (US00287Y1091): focus on Humira erosion and Skyrizi growth after latest quarterly repor
AbbVie is undergoing a significant transition as its blockbuster drug Humira faces increasing biosimilar competition, while newer immunology drugs, Skyrizi and Rinvoq, become key growth drivers. The company's latest quarterly results highlight both the impact of Humira's decline and the strong performance of its new portfolio, maintaining its focus on immunology, oncology, and neuroscience. For US investors, AbbVie's market presence, dividend history, and exposure to domestic healthcare policy make it a closely observed stock.
Enveric Biosciences Reports Financial Results and Provides Corporate Update for First Quarter 2026
Enveric Biosciences reported financial results for the first quarter of 2026, highlighting continued advancement of its lead candidate EB-003 towards clinical trials and strengthening its intellectual property portfolio. The company also announced the withdrawal of a Post-Grant Review petition by AbbVie, Inc. concerning patents relevant to bretisilocin. Enveric raised approximately $1.5 million from a registered direct offering during the quarter, with additional funds secured post-quarter, bringing its cash balance to $10.3 million as of May 15, 2026, expected to fund operations into Q1 2027.
How Investors Are Reacting To Apogee Therapeutics (APGE) Trial Win Amid Wider Losses And Insider Sales
Apogee Therapeutics (APGE) reported widening net losses in Q1 2026 but saw its developmental inflammation therapy meet trial objectives. Despite this clinical success, which has kept Wall Street analysts positive, the company faces typical early-stage biotech risks such as widening losses, insider share sales, and ongoing financing needs. The article suggests focusing on future Phase 2 and Phase 3 milestones while being aware of potential shareholder dilution and financing risks.
AbbVie Inc stock (US00287Y1091): arthritis drug data and dividend keep the spotlight on the pharma g
AbbVie Inc. is drawing investor attention in May 2026 due to new clinical data for its immunology drug Skyrizi in inflammatory arthritis and its consistent quarterly dividend payout. The company's core business model focuses on high-margin branded drugs and significant R&D, with Skyrizi and Rinvoq leading its immunology franchise and aesthetics contributing meaningfully post-Allergan acquisition. AbbVie's performance is relevant for US investors, being a major constituent of equity indices and a key dividend payer, though it faces competition, regulatory scrutiny, and the challenge of successfully launching new products.
AbbVie Inc. $ABBV Shares Sold by WealthPlan Investment Management LLC
WealthPlan Investment Management LLC reduced its stake in AbbVie Inc. (NYSE:ABBV) by 21.7% in the fourth quarter, selling over 16,000 shares. Despite this, AbbVie reported impressive Q1 results, surpassing EPS and revenue expectations, and maintaining a robust 3.3% dividend yield. Analysts generally hold a "Moderate Buy" rating for the stock with a consensus target price of $253.43.
